huCdc7激酶及其与肿瘤的关系

Cdc7在人类细胞里的同源蛋白huCdc7几乎在人体所有组织中均有表达，在细胞周期中huCdc7可以通过磷酸化作用行使调控DNA复制起始的功能，同时也可通过参与ATR/Chk1途径调控细胞周期中DNA损伤的S期检验点．而近来研究发现，huCdc7表达水平的改变也参与恶性肿瘤的发生发展，在肿瘤细胞里huCdc7能加快肿瘤细胞的异常增殖同时对抗化疗药物也起到关键性的作用．目前，huCdc7已成为治疗肿瘤的一个重要靶标，最新发现的huCdc7有效抑制剂——PHA-767491在癌症治疗中显示出了独特的抑制肿瘤的作用，并且对正常细胞无毒副作用．因此，对huCdc7激酶及其抑制剂的进一步深入研究有望为临床治疗肿瘤开辟新的途径．

huCdc7 kinase and relationship with tumor

Cdc7 protein, a serine-threonine kinase, acts as a regulator in the initiation of DNA replication by phosphorylation, and is also implicated in S phase checkpoint response via the interaction with ATR/Chk1 pathway. A human homologue of Cdc7 (huCdc7) is ubiquitously expressed in human tissues, while is overexpressed and activated in a high level in many tumor cell lines. Recent studies show huCdc7 kinase play an important role in the development and chemical resistance of cancer, and huCdc7 has been accepted as a new biomarker of tumor. More recently, it has been reported that PHA-767491, an efficient inhibitor of huCdc7, suppresses tumor growth without the damage of normal cells. Thus, the insight into huCdc7 kinase and its inhabitors would provide a novel strategy for tumor treatment.